Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04056299 · ClinicalTrials.gov registry record · Phase 2
Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy
A Phase 2 study, sponsored by Aimmune Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT04056299 is a Phase 2 study that was terminated before completion, run by Aimmune Therapeutics. The registered enrollment target is 15 participants.
The verdict
NCT04056299, a Phase 2 study, was terminated before completion, sponsored by Aimmune Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
To determine the efficacy and safety of AR201 in a characterized oral desensitization immunotherapy (CODIT™) regimen in hen egg-allergic subjects aged 4 to 26 years, inclusive.
Interventions
- BIOLOGICAL AR201 powder
- BIOLOGICAL Placebo powder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2019-08-20 |
| Est. Completion | 2020-12-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04056299
The ClinicalTrials.gov registry entry for NCT04056299 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aimmune Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AR201 powder is the first listed.
NCT04056299 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04056299 about?
NCT04056299 is a clinical study titled "Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy". To determine the efficacy and safety of AR201 in a characterized oral desensitization immunotherapy (CODIT™) regimen in hen egg-allergic subjects aged 4 to 26 years, inclusive.
What is the current status of trial NCT04056299?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2019-08-20. Estimated completion is 2020-12-28.
What interventions are being tested in trial NCT04056299?
The interventions under investigation include: AR201 powder (BIOLOGICAL), Placebo powder (BIOLOGICAL).
Who is sponsoring clinical trial NCT04056299?
This trial is sponsored by Aimmune Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.